Bourne Partners is a global healthcare merchant banking and financial advisory firm that concentrates solely on providing services and capital to middle market healthcare companies through four business segments: healthcare merchant banking, investment banking, management consulting, and alternative assets. The firm offers financial advisory, investment, and consulting services, as well as makes direct and co-investments in healthcare companies. It provides a full spectrum of investment banking services including capital sourcing, mergers and acquisitions, and asset divestitures. Bourne Partners also leverages its network to help companies with operations, manufacturing, sales, marketing, costs, and regulatory affairs through its management consulting segment.

1. Corporate Overview
Bourne Partners is a global healthcare merchant banking and
financial advisory firm. Unlike generalist firms, Bourne Partners
concentrates solely on providing world-class service and capital to
middle market healthcare companies around the globe through our
four business segments:
HEALTHCARE MERCHANT BANKING
Bourne Partners offers financial advisory, investment and consulting
services for established, middle-market healthcare and pharmaceutical
companies across the globe. We also make direct and co-investments in
healthcare companies.
INVESTMENT BANKING*
Bourne Partners offers a full spectrum of investment banking services:
capital sourcing, sell side mergers & acquisitions and asset divestitures,
buy side mergers & acquisitions and business development.
MANAGEMENT CONSULTING
Through Bourne Partners Management Consulting, we leverage our
network of Executive Partners and Operating Partners to execute strategies
for improving operations, manufacturing, sales management, marketing,
cost containment, supply chain logistics, legal affairs and QA/Regulatory
affairs.
ALTERNATIVE ASSETS
Bourne Partners Alternative Assets offers strategic investments
opportunities, including direct investments and co-investments in privately-
held companies as well as investments in top tier private equity sponsors
such as The Carlyle Group, Cerberus Capital Management and Irving Place
Capital.
Advisory Services*
Sector Focus
 Pharmaceuticals
 Consumer Health
 Healthcare Services
 Healthcare IT
 Med. Device / Diagnostics
Types of Advisory Work
 M&A
 Licensing / Partnering
 Private Placements
 Strategic Consulting
Transaction Values
 $25 - $300mm
Investing Activities
 Healthcare and Other Select Sectors
$500k - $5mm
 Co-Investments with Partner Private
Equity Sponsors in Middle Market
Investment Transactions
($25-$300m+)
 Private Equity Fund Investment
 Fund of Funds – Top Tier Private
Equity and Venture Fund Managers
www.bourne-partners.com | 550 South Caldwell Street, Suite 900, Charlotte, NC 28202 | Phone: +1 (704) 552-8407
EXECUTIVE TEAM
Our team of former healthcare executives and seasoned investment bankers
operates as active partners to you and your business. We have raised over $2
billion in equity and debt capital and executed over $2 billion in M&A
transactions all within the healthcare sector. We maintain a close relationship
and an active calling effort with more than 250 healthcare companies around
the world. We are also proud that more than 80% of our clients since 2005
have returned for repeat transaction advisory.
A full spectrum of services, tailored
to your business.
*Investment Banking services are provided by Bourne Partners Securities, LLC member FINRA and SIPC

2. Announces the acquisition of a portfolio of
five branded pharmaceutical products from
The undersigned served as exclusive financial
advisor to Covis Pharma in the structuring
of this transaction
www.bourne-partners.com | 550 South Caldwell Street, Suite 900, Charlotte, NC 28202 | Phone: +1 (704) 552-8407
Select Tombstones
Select Clients
Select Investments (Direct, Co-investments, Funds)
Announces the acquisition of a portfolio of
five branded pharmaceutical products from
The undersigned served as exclusive financial
advisor to Covis Pharma in the structuring
of this transaction
Announces the sale of the Canadian rights to
Delatestryl® and Viroptic® to
The undersigned served as exclusive financial
advisor to Theramed Corporation in the
structuring of this transaction
Announces the exclusive licensing of Epliga™
in certain Latin American countries to
The undersigned served as exclusive financial
advisor to Supernus Pharmaceuticals in the
structuring of this transaction
Announces the
acquisition of
The undersigned served as exclusive financial
advisor to Azur Pharma limited in the
structuring of this transaction